HK1084690A1 - An expression cassette and vector for transient or stable expression of exogenous molecules - Google Patents

An expression cassette and vector for transient or stable expression of exogenous molecules

Info

Publication number
HK1084690A1
HK1084690A1 HK06104824.8A HK06104824A HK1084690A1 HK 1084690 A1 HK1084690 A1 HK 1084690A1 HK 06104824 A HK06104824 A HK 06104824A HK 1084690 A1 HK1084690 A1 HK 1084690A1
Authority
HK
Hong Kong
Prior art keywords
expression
vector
transient
expression cassette
cassette
Prior art date
Application number
HK06104824.8A
Other languages
English (en)
Inventor
William P Sisk
Holly Prentice
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of HK1084690A1 publication Critical patent/HK1084690A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Paints Or Removers (AREA)
  • Tents Or Canopies (AREA)
HK06104824.8A 2003-02-14 2006-04-24 An expression cassette and vector for transient or stable expression of exogenous molecules HK1084690A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44817903P 2003-02-14 2003-02-14
PCT/US2004/004407 WO2004074439A2 (fr) 2003-02-14 2004-02-13 Cassette et vecteur d'expression pour l'expression transitoire ou stable de molecule exogenes

Publications (1)

Publication Number Publication Date
HK1084690A1 true HK1084690A1 (en) 2006-08-04

Family

ID=32908549

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06104824.8A HK1084690A1 (en) 2003-02-14 2006-04-24 An expression cassette and vector for transient or stable expression of exogenous molecules

Country Status (22)

Country Link
US (2) US7494805B2 (fr)
EP (1) EP1594955B1 (fr)
JP (2) JP2006517802A (fr)
KR (1) KR20050101554A (fr)
CN (1) CN1774500B (fr)
AT (1) ATE553185T1 (fr)
AU (1) AU2004213797B2 (fr)
BR (1) BRPI0407487A (fr)
CA (1) CA2515481A1 (fr)
DK (1) DK1594955T3 (fr)
EA (2) EA200700469A1 (fr)
ES (1) ES2384973T3 (fr)
HK (1) HK1084690A1 (fr)
IL (1) IL170178A (fr)
IS (1) IS7974A (fr)
MX (1) MXPA05008523A (fr)
NO (1) NO20054202L (fr)
NZ (1) NZ542316A (fr)
PL (1) PL378110A1 (fr)
RS (1) RS20050614A (fr)
WO (1) WO2004074439A2 (fr)
ZA (1) ZA200506413B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004213797B2 (en) 2003-02-14 2009-09-17 Biogen Ma Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
EA012241B1 (ru) 2003-09-19 2009-08-28 Янссен Фармацевтика, Н.В. 4-((феноксиалкил)тио)феноксиуксусные кислоты и их аналоги
EA010059B1 (ru) * 2003-10-14 2008-06-30 Байоджен Айдек Ма Инк. Flp-опосредованная рекомбинация
US7569362B2 (en) * 2004-03-15 2009-08-04 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
AU2007333010A1 (en) * 2006-10-18 2008-06-19 The Scripps Research Institute Genetic incorporation of unnatural amino acids into proteins in mammalian cells
WO2011017319A1 (fr) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Méthodes de traitement de troubles associés à la polymérisation d'une protéine
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
UY33126A (es) * 2009-12-21 2011-07-29 Sanofi Sa Animal transgénico no humano y sus usos
AU2010339858B2 (en) * 2009-12-21 2016-01-28 Sanofi Transgenic non-human animal and uses thereof
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
WO2013158664A2 (fr) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Utilisation de virus modifiés pour tuer spécifiquement les cellules sénescentes
WO2014042923A1 (fr) 2012-09-13 2014-03-20 Indiana University Research & Technology Corporation Compositions et systèmes pour conférer une résistance à une maladie à des plantes et leurs procédés d'utilisation
AU2013359419B2 (en) 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
MX2015013842A (es) * 2013-03-30 2017-01-23 Usha Biotech Ltd Metodos y constructos para expresar proteinas biologicamente activas en celulas de mamifero.
WO2015162930A1 (fr) * 2014-04-24 2015-10-29 一般社団法人 医療産業イノベーション機構 Procédé permettant d'améliorer l'expression des protéines, et composition pour l'expression des protéines
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US11415263B2 (en) * 2020-03-20 2022-08-16 Edwards Vacuum Llc Conversion kit for a support frame, a support frame and an integrated vacuum system mounted in a support frame

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE69233051T2 (de) 1991-10-25 2004-03-11 Immunex Corp., Seattle Antikörper gegen CD40-L
UA41319C2 (uk) 1992-04-02 2001-09-17 Сембайозіс Дженетікс Інк. Спосіб експресії послідовності днк,що представляє інтерес,у клітині насіння,химерний ген,експресуюча касета,ізольована регуляторна ділянка транскрипції,спосіб зміни специфічного для насіння метаболізму, спосіб одержання нових поліпептидів у насінні,ізольована днк, спосіб експресії послідовності днк,що представляє інтерес,у рослині-хазяїні,спосіб одержання очищеного поліпептиду,що представляє інтерес,спосіб одержання поліпептиду, що представляє інтерес, в олійному тілі
EP0831854A4 (fr) 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc Oligonucleotides de grande purete chirale ayant des liaisons phosphorothioate
WO1996040918A2 (fr) 1995-06-07 1996-12-19 Immunex Corporation Muteine de cd40l
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6087129A (en) * 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
EP0914441A2 (fr) 1996-04-23 1999-05-12 The Wistar Institute Of Anatomy And Biology Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations
CA2297375A1 (fr) * 1997-07-24 1999-02-04 Valentis, Inc. Systeme d'expression de ghrh et procedes d'utilisation
CA2318663A1 (fr) * 1998-01-16 1999-07-22 California Pacific Medical Center Research Institute Methodes et compositions d'administration genique
EP0953639A1 (fr) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH Anticorps dirigé contre FAPalpha pouvant être produit avec une efficacité accrue
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
DE69940899D1 (de) * 1998-05-27 2009-06-25 Genzyme Corp AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung
EP1092768A1 (fr) * 1999-10-16 2001-04-18 ARTEMIS Pharmaceuticals GmbH Construction pour le piègeage conditionel et la disruption de gènes
AU2001264488A1 (en) 2000-06-07 2001-12-17 Smittskyddsinstitutet Gene expression cassette and its use
AU7061401A (en) 2000-07-05 2002-01-14 Transgene Sa Chimeric promoters for controlling expression in smooth muscle cells
JP2002233374A (ja) * 2001-02-06 2002-08-20 Japan Science & Technology Corp 遺伝子導入及び／又は遺伝子欠損非ヒト動物作製用ベクター
DE10133407A1 (de) 2001-07-13 2003-01-23 Basf Ag Expressionskassetten zur transgenen Expression von Nukleinsäuren
US20030235823A1 (en) 2002-06-24 2003-12-25 The University Of Alabama Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation
AU2004213797B2 (en) * 2003-02-14 2009-09-17 Biogen Ma Inc. An expression cassette and vector for transient or stable expression of exogenous molecules

Also Published As

Publication number Publication date
WO2004074439A3 (fr) 2004-10-28
PL378110A1 (pl) 2006-03-06
CN1774500A (zh) 2006-05-17
IS7974A (is) 2005-08-11
BRPI0407487A (pt) 2006-02-14
EA200501296A1 (ru) 2006-04-28
JP2006517802A (ja) 2006-08-03
EP1594955A2 (fr) 2005-11-16
NO20054202D0 (no) 2005-09-09
CN1774500B (zh) 2011-03-02
ZA200506413B (en) 2006-04-26
DK1594955T3 (da) 2012-06-25
MXPA05008523A (es) 2005-10-20
AU2004213797A1 (en) 2004-09-02
KR20050101554A (ko) 2005-10-24
JP2010213718A (ja) 2010-09-30
ATE553185T1 (de) 2012-04-15
EP1594955B1 (fr) 2012-04-11
EP1594955A4 (fr) 2006-07-19
RS20050614A (en) 2007-12-31
US7494805B2 (en) 2009-02-24
ES2384973T3 (es) 2012-07-16
AU2004213797B2 (en) 2009-09-17
CA2515481A1 (fr) 2004-09-02
US20060141625A1 (en) 2006-06-29
IL170178A (en) 2011-12-29
EA200700469A1 (ru) 2008-10-30
EA008439B1 (ru) 2007-06-29
US20100158879A1 (en) 2010-06-24
NO20054202L (no) 2005-11-11
WO2004074439A9 (fr) 2004-12-23
WO2004074439A2 (fr) 2004-09-02
NZ542316A (en) 2006-04-28

Similar Documents

Publication Publication Date Title
HK1084690A1 (en) An expression cassette and vector for transient or stable expression of exogenous molecules
DE60035032D1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
IL179441A (en) Method of measuring the activity of egln enzyme and of identifying an agent that modulates activity of said enzyme
GB2445482A (en) Searching data storage systems and devices
PL331332A1 (en) Cell adhesion inhibitors
DK1601776T3 (da) Ekspressionsvektorer omfattende mCmV-IE2-promotoren
MY117709A (en) Adhesion promoters containing silane, carbamate or urea, and donor or acceptor functionality
DE60316984D1 (de) Benzoylsulfonamide als antitumor-mittel
IL187489A (en) Substrate for rpn11 meteloprotase containing a jamm motif
ATE433458T1 (de) Modulatoren von ship-1
ATE513040T1 (de) Zinkfingerdomänenbibliotheken
ATE404602T1 (de) Wässrige polyurethanzubereitungen
AU4278196A (en) A scintillation proximity assay for n-acetylgalactosaminyltransferase activity
EP1506313A4 (fr) Methodes de modulation de la desacetylase mitochondriale nad-dependante
IL142596A0 (en) Baculovirus expression system
ATE268322T1 (de) Inhibitoren der tryptase
DE60326831D1 (en) Hepatitis-c-virus-testsysteme
WO2004104030A3 (fr) Peptides modulateurs de l'activite du facteur de transcription engrailed
DE60335525D1 (de) 2,3-Diaryl-Pyrazolidine Derivate als Neurotensin abbauende Enzyme-Inhibitoren
WO2023235567A3 (fr) Interfaces utilisateur personnalisées
WO2001012838A3 (fr) Composes modulateurs de l'activite d'un recepteur d'acide lysophosphatidique (lpa)
WO2003060104A3 (fr) Micro-organismes presentant une activite sur la cellulose
WO2001077341A3 (fr) Heparanase de mammifere
WO2001020335A3 (fr) Procedes de modulation de la proliferation cellulaire
TR200102093T2 (tr) Organ koruyucu çözeltiler

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240212